glp 1 ckd benefit GLP-1 and the kidney: from physiology to pharmacology and outcomes in diabetes Glucagon-Like Peptide-1 Receptor Agonist Use

Other genes, although with ARE motifs, present CpG islands in their proximal promoters such as GCLC and GCLM, which are characterized by significant association of active histone codes such as H3K4Me1-3, H3K9Ac, H3K27Ac, and H3K79Me2, suggesting a regulatory role of CpG islands in chromatin modifications

However, because these drugs now straddle diabetes and obesity treatment, coverage rules become complex (for example, a plan may cover them for diabetes but not for weight loss)

2020;63A(3):20919

We present clinical strategies for adverse event mitigation, monitoring recommendations, contraindications, and practical considerations for treatment discontinuation or switching